OVERVIEW

Prostate cancer is the most common urologic malignancy and the most common solid tumor found in men. This activity will address the scientifi c data available on the current and emerging treatment options for prostate cancer. It will also address the areas of prevention and screening, diagnosis and treatment of localized disease, issues related to hormone deprivation, diagnosis and treatment of advanced and refractory prostate cancer, novel treatment options, and the role of the urologist as part of the treatment team. The American Cancer Society estimates that there were about 186,320 new cases of prostate cancer in the United States in 2008. About 28,660 men will die of this disease this year. While 1 man in 6 will get prostate cancer during his lifetime, only 1 man in 35 will die of this disease. More than 2 million men in the United States who have had prostate cancer at some point are still alive today because the death rate for prostate cancer is going down and detection of the disease is occurring earlier. With the use of new and combined treatments, however, the frequency and variety of complications have differed from those previously reported, and despite these advances, no consensus has emerged regarding the optimal treatment for the most common patients with prostate cancer, those diagnosed with localized disease (accounting for 91% of 234,460 of men in the United States diagnosed with prostate cancer annually).

TARGET AUDIENCE

This activity has been developed and is intended for urologists, oncologists, urologic oncologists, and any medical professional who diagnoses or treats patients with prostate cance.

 Download a PDF of the full issue